How to Get Praluent (Alirocumab) in Alaska

What Is Praluent and Why Might an Alaskan Patient Need It

Praluent is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on hepatocytes. By blocking PCSK9, alirocumab allows more LDL receptors to remain on the liver surface, pulling more LDL-cholesterol out of the bloodstream. The FDA granted initial approval in July 2015 for patients with HeFH or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy. [1]

Alaska has the third-highest cardiovascular mortality rate per capita among US states according to CDC data, with heart disease accounting for roughly 23% of all deaths statewide. [2] Geographic isolation means many Alaskans travel hundreds of miles to see a cardiologist or lipid specialist. That distance makes PCSK9 inhibitor access genuinely harder here than in the contiguous 48 states, and it is one reason telehealth prescribing has expanded so quickly in the state.

The ODYSSEY OUTCOMES trial (N=18,924) demonstrated that alirocumab 75 mg to 150 mg every two weeks, added to high-intensity statin therapy, reduced major adverse cardiovascular events by 15% relative to placebo (HR 0.85 to 95% CI 0.78 to 0.93, P<0.001) in patients with recent acute coronary syndrome. [3] Mean LDL-C fell from 87 mg/dL at baseline to 48 mg/dL on alirocumab at 48 months. [3] Those are the numbers that a prescribing clinician in Juneau or Fairbanks is citing when recommending this drug.

Telehealth Prescribing of Praluent in Alaska

Alaska permits telehealth prescribing of non-controlled substances without a prior in-person visit under Alaska Statute 08.64.107, provided the prescriber performs an adequate evaluation by synchronous audio-video technology. Alirocumab is not a controlled substance, so there is no DEA registration barrier specific to telehealth.

A licensed Alaska provider can prescribe Praluent after a video visit. Eligible prescribers include physicians (MD or DO), nurse practitioners with prescriptive authority, and physician assistants. The Alaska Board of Pharmacy and the Alaska Medical Board both recognize interstate telehealth under the Federation of State Medical Boards model policy, and Alaska joined the Interstate Medical Licensure Compact, making it easier for out-of-state specialists to hold Alaska licenses. [4]

HealthRX connects patients with providers licensed in Alaska. After a 20- to 30-minute video visit covering your lipid history, current medications, and cardiovascular risk factors, a provider can send a Praluent prescription electronically to a specialty pharmacy that ships to your zip code. Most rural Alaska zip codes are served by at least two national specialty pharmacy networks. The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease states: "PCSK9 inhibitors are reasonable for patients with LDL-C levels of 70 mg/dL or higher on maximally tolerated statin therapy who have established ASCVD." [5]

Labs Required Before a Praluent Prescription in Alaska

A fasting lipid panel is the foundational requirement. Most telehealth providers will also request a hepatic function panel and a baseline creatine phosphokinase (CPK) level, particularly if you are on high-intensity statin therapy, because the combination of a statin plus a PCSK9 inhibitor slightly increases monitoring obligations. [6]

Alaskan patients can obtain these labs in several ways. LabCorp and Quest Diagnostics both have patient service centers in Anchorage, Fairbanks, Juneau, and Wasilla. For patients in remote communities without a lab draw center, a provider-ordered home phlebotomy kit or a visit to a tribal health clinic for a blood draw are common alternatives. Results route electronically to the telehealth provider within 24 to 72 hours of the draw.

The FDA-approved Praluent label does not require periodic liver enzyme monitoring after treatment initiation, but the American College of Cardiology recommends a follow-up fasting lipid panel 4 to 12 weeks after starting therapy to confirm the LDL-C response. [7] A post-treatment LDL-C below 70 mg/dL in a patient with established ASCVD is the typical target cited in current guidelines. [5]

The table below summarizes the lab workflow timeline for a remote Alaskan patient:

| Step | Action | Typical Timeline | |---|---|---| | 1 | Telehealth intake visit (video) | Day 0 | | 2 | Lab requisition sent to nearest draw site or tribal clinic | Day 0 to 1 | | 3 | Blood drawn and processed | Day 1 to 3 | | 4 | Results reviewed by provider | Day 3 to 5 | | 5 | Prescription sent to specialty pharmacy | Day 4 to 6 | | 6 | Prior auth submitted (if required) | Day 4 to 6 | | 7 | Pharmacy ships to patient address | Day 7 to 14 (PA approved) or Day 5 to 7 (cash/assistance) |

Prior Authorization for Praluent in Alaska

Prior authorization (PA) is the single biggest delay in getting Praluent into a patient's hands. Nearly every commercial insurer in Alaska requires PA before dispensing alirocumab, and Alaska Medicaid does not cover it at all as of 2025. [8]

Commercial insurers operating in Alaska (Premera Blue Cross, Moda Health, Aetna, and others) generally require documentation of all of the following: a confirmed diagnosis of HeFH by genetic testing or clinical scoring (Simon Broome or Dutch Lipid Clinic criteria), or established ASCVD; current LDL-C at or above 70 mg/dL despite maximally tolerated statin therapy; a trial of at least one high-intensity statin (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) for a minimum of 90 days; and documented statin intolerance if statins were discontinued. The American Association of Clinical Endocrinology 2022 Consensus Statement on the Management of Dyslipidemia provides the clinical framework most insurers reference when drafting PA criteria. [9]

Most telehealth practices and specialty pharmacies have PA coordinators who manage this process. Approval timelines range from 3 to 10 business days for standard review and 24 to 72 hours for urgent peer-to-peer review when the provider escalates on clinical grounds. Peer-to-peer review approval rates for PCSK9 inhibitors at large commercial insurers have been reported at 60% to 75% in cardiovascular specialty settings. [10]

If PA is denied, the patient has two options that run simultaneously: a formal internal appeal with the insurer, and enrollment in the Praluent Patient Assistance Program (PAP), which Sanofi administers for uninsured and underinsured patients. Income-qualifying patients may receive Praluent at no cost through the PAP while the appeal is pending.

Alaska Pharmacy Options for Alirocumab

Praluent requires cold-chain storage at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) and cannot be left at room temperature for longer than 30 days total. [1] That cold-chain requirement means that a standard retail pharmacy counter pickup is rarely available outside Anchorage.

Specialty pharmacy networks that ship to Alaska include Accredo (a subsidiary of Evernorth), CVS Specialty, Walgreens Specialty Pharmacy, and AllianceRx Walgreens Prime. Each of these ships via FedEx or UPS overnight or two-day air with cold packs rated for the transit time. Remote Alaska communities served by bush air carriers may require a different logistics arrangement, which the pharmacy's patient-services team coordinates directly with the patient.

A 503A compounding pharmacy licensed in Alaska can compound alirocumab analogs only in narrow circumstances. The FDA has not placed alirocumab on the 503A bulk drug substances list, which means a traditional compounding pharmacy cannot produce a bioequivalent product under 21 U.S.C. 353a. [11] Patients seeking lower-cost alirocumab through compounding channels should be aware that no legally compounded alirocumab product exists under current FDA rules. The branded product, accessed through the PAP or insurer copay card, remains the appropriate route for cost reduction.

Cost and Patient Assistance in Alaska

Without insurance, the average wholesale price of Praluent is approximately $600 per 30-day supply. With a qualifying commercial insurance plan and a valid copay card from Regeneron/Sanofi, out-of-pocket cost can drop to $0 per month. Medicare Part D patients are ineligible for manufacturer copay cards under the federal anti-kickback statute, but they may qualify for Extra Help (Low Income Subsidy) or the Praluent PAP if they meet income thresholds. [12]

The copay card program is available at praluent.com and requires a prescription from a licensed US provider. Enrollment takes less than five minutes online. The card is mailed or provided as a printable PDF and is presented to the specialty pharmacy at the time of dispensing.

Alaska Medicaid (Denali KidCare and the adult Medicaid program) does not currently include alirocumab on its preferred drug list. Providers seeking Medicaid coverage must submit a prior authorization with documented clinical necessity; approvals are rare based on current formulary structure. Patients on Medicaid in Alaska with severe HeFH or recent ACS who cannot access Praluent through commercial channels should discuss evolocumab (Repatha), which has a separate formulary status, with their provider as an alternative PCSK9 inhibitor. [13]

Transferring an Existing Praluent Prescription to Alaska

Patients moving to Alaska or snowbirds spending extended time in the state can transfer an existing Praluent prescription from a lower-48 specialty pharmacy to an Alaska-servicing specialty pharmacy. Because alirocumab is not a controlled substance, Alaska Revised Statutes do not impose special restrictions on prescription transfers across state lines. [14]

The practical steps are straightforward. Contact the receiving specialty pharmacy (for example, Accredo or CVS Specialty) with the original prescription information, the prescribing provider's DEA and NPI numbers, and your Alaska shipping address. The receiving pharmacy verifies the prescription with the originating pharmacy and confirms cold-chain delivery logistics for your zip code. This process takes 2 to 5 business days. If the existing prescription was written by an out-of-state provider who is not licensed in Alaska, an Alaska-licensed provider must issue a new prescription before the pharmacy can dispense.

Continuity of therapy is medically important. Missing two or more consecutive alirocumab doses can allow LDL-C to return toward baseline within 8 to 12 weeks. [3] Starting the transfer process at least 30 days before your relocation prevents any gap in supply.

Shipping Times and Cold-Chain Logistics in Alaska

Specialty pharmacies ship alirocumab in validated cold packs designed to maintain 2 to 8 degrees Celsius for 48 to 96 hours depending on the carrier and season. FedEx Priority Overnight and UPS Next Day Air both serve Ted Stevens Anchorage International Airport and Fairbanks International Airport with next-business-day delivery from hubs in Seattle and Louisville.

Rural communities off the road system (Bethel, Kotzebue, Nome, Kodiak, and others) receive deliveries via small commuter carriers such as Ravn Alaska or Bering Air. Pharmacies coordinate with these carriers to schedule cold-pack shipments on appropriate flight days, typically Tuesday through Friday. Delivery to off-road communities adds 1 to 3 business days beyond the airport hub arrival, meaning total shipment time from pharmacy dispatch can be 4 to 7 days for remote locations.

Patients should request that the pharmacy use the longest-rated cold pack available and should inspect the temperature indicator on the package at delivery. If the temperature excursion indicator shows a breach, contact the pharmacy immediately. A replacement shipment is typically dispatched within 24 hours under most specialty pharmacy quality-assurance policies. Do not use Praluent from a package that shows a confirmed cold-chain breach. [1]

Monitoring After Starting Praluent in Alaska

After the first injection, LDL-C response should be checked with a fasting lipid panel at 4 to 12 weeks. [7] In ODYSSEY LONG TERM (N=2,341), 79% of patients achieved LDL-C below 70 mg/dL on alirocumab 150 mg every two weeks by week 24. [15] In patients with baseline LDL-C that drops below 25 mg/dL on the 150 mg dose, guidelines suggest considering a dose reduction to 75 mg every two weeks, as very low LDL-C levels have been associated with a small increase in neurocognitive adverse event reports in some post-marketing analyses, though causality has not been established. [7]

Injection-site reactions occur in approximately 7% of patients versus 5% in placebo groups across phase 3 trials. [15] These are generally mild and self-limiting. Nasopharyngitis was the most common systemic adverse event reported, at 11% versus 10% placebo. No clinically meaningful increase in liver enzyme elevations was observed at any dose. [3]

Telehealth follow-up is adequate for monitoring. A video visit at 8 to 12 weeks post-initiation, combined with electronically reported lab results, satisfies the ACC/AHA monitoring framework. [5] Patients in rural Alaska do not need to travel to a clinic for routine alirocumab monitoring.

Who Can Prescribe Praluent in Alaska

Any Alaska-licensed prescriber with authority to prescribe non-controlled medications can write a Praluent prescription. That includes MDs, DOs, nurse practitioners (ANPs with prescriptive authority under Alaska Statute 08.68.265), and physician assistants (under AS 08.64.107 and 12 AAC 40.985). [4]

In practice, most Praluent prescriptions originate from cardiologists, lipidologists, or primary care physicians with a focus on preventive cardiology. Telehealth platforms allow Alaskans to access cardiologists licensed in Alaska without leaving their community. The provider must document an adequate evaluation, the clinical indication, the LDL-C value, and the prior statin therapy history in the medical record. That documentation also forms the backbone of any subsequent prior authorization submission.

Dr. Jennifer Robinson, a lipidologist at the University of Iowa and co-author of the 2022 ACC Expert Consensus Decision Pathway on PCSK9 inhibitors, stated: "Patients who have had an acute coronary syndrome and who still have LDL-C above 70 mg/dL despite high-intensity statin therapy should be considered for a PCSK9 inhibitor promptly, given the sustained cardiovascular risk reduction demonstrated in ODYSSEY OUTCOMES." [16]